Entacapone

Bibliography

• de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5(6):525-35
   PubMed Web of Science ®Google Scholar
• Foley P, Riederer P. Pathogenesis and preclinical course of Parkinson's disease. J Neural Transm Suppl 1999;56:31-74
   PubMedGoogle Scholar
• Przuntek H, Muller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 2004;111(2):201-16
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351(24):2498-508
   PubMed Web of Science ®Google Scholar
• Rascol O. Monoamine oxidase inhibitors – is it time to up the TEMPO? Lancet Neurol 2003;2(3):142-3
   PubMed Web of Science ®Google Scholar
• Muller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin Pharmacother 2006;7(13):1715-30
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284(15):1931-8
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61(4):561-6
   PubMed Web of Science ®Google Scholar
• Block G, Liss C, Reines S, Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997;37(1):23-7
   PubMed Web of Science ®Google Scholar
• Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5- year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999;53(5):1012-9
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Piccini P, Bailey DL, 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002;43(3):201-7
   PubMed Web of Science ®Google Scholar
• Gervas JJ, Muradas V, Bazan E, Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 1983;33(3):278-82
   PubMed Web of Science ®Google Scholar
• Guttman M, Leger G, Reches A, Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Mov Disord 1993;8(3):298-304
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Gancher ST, Merrick D. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol 1987;21(6):584-8
   PubMed Web of Science ®Google Scholar
• Mannisto PT. Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors. Adv Pharmacol 1998;42:324-8
   PubMedGoogle Scholar
• Sawle GV, Burn DJ, Morrish PK, The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 1994;44(7):1292-7
   PubMed Web of Science ®Google Scholar
• Hauser RA, Panisset G, Abbruzzese G, Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2008;24:39-48
   Google Scholar
• Brooks DJ, Agid Y, Eggert K, Treatment of end-of-dose wearing-off in Parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 2005;53(4):197-202
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Stern M, Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004;61(10):1563-8
   PubMed Web of Science ®Google Scholar
• Poewe WH, Deuschl G, Gordin A, Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105(4):245-55
   PubMed Web of Science ®Google Scholar
• Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology 2004;62(1 Suppl 1):S39-46
   PubMed Web of Science ®Google Scholar
• Baas H, Beiske AG, Ghika J, Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63(4):421-8
   PubMed Web of Science ®Google Scholar
• Benabou R, Waters C. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease. Expert Opin Drug Saf 2003;2(3):263-7
   PubMedGoogle Scholar
• Blandini F, Nappi G, Fancellu R, Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. J Neural Transm 2003;110(8):911-22
   PubMed Web of Science ®Google Scholar
• Muller T, Woitalla D, Schulz D, Tolcapone increases maximum concentration of levodopa. J Neural Transm 2000;107(1):113-9
   PubMed Web of Science ®Google Scholar
• Russ H, Muller T, Woitalla D, Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch Pharmacol 1999;360(6):719-20
   PubMed Web of Science ®Google Scholar
• Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov Disord 2007;22(1):14-9
   PubMed Web of Science ®Google Scholar
• Factor SA, Molho ES, Feustel PJ, Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin Neuropharmacol 2001;24(5):295-9
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 2004;62(1 Suppl 1):S72-81
   PubMed Web of Science ®Google Scholar
• Muller T, Erdmann C, Muhlack S, Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels. Mov Disord 2006;21(3):332-6
   PubMed Web of Science ®Google Scholar
• Nutt JG. Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 2000;55(11 Suppl 4):S33-7
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000;55(11 Suppl 4):S72-7
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 1996;30(6):463-81
   PubMed Web of Science ®Google Scholar
• Mouradian MM, Heuser IJ, Baronti F, Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25(5):523-6
   PubMed Web of Science ®Google Scholar
• Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(4 Suppl 1):S2-9
   PubMed Web of Science ®Google Scholar
• Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 1999;246(12):1127-33
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16(3):448-58
   PubMed Web of Science ®Google Scholar
• Cubo E, Gracies JM, Benabou R, Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol 2001;58(9):1379-82
   PubMed Web of Science ®Google Scholar
• Kostic VS, Marinkovic J, Svetel M, The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol 2002;9(1):9-14
   PubMed Web of Science ®Google Scholar
• Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005;20(3):342-4
   PubMed Web of Science ®Google Scholar
• Meiler B, Andrich J, Muller T. Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion. Mov Disord 2008;23(1):145-6
   PubMed Web of Science ®Google Scholar
• Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006;45(2):109-36
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342(20):1484-91
   PubMed Web of Science ®Google Scholar
• Rascol O. The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. J Neurol 2000;247(Suppl 2):II51-II57
   PubMedGoogle Scholar
• Muller T, Erdmann C, Muhlack S, Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. J Neural Transm 2006;113(10):1441-8
   PubMed Web of Science ®Google Scholar
• Stocchi F, Kieburtz K, Rascol O, Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson's disease: the Stride-PD Study. Ann Neurol 2010; In press
   Google Scholar
• Stocchi F, Kakarieka A, Kieburtz K, ; on behalf of the STRIDE-PD investigators. The STRIDE-PD (Stalevo Reduction in Dyskinesia Evaluation) Study. Late breaking abstracts: the Movement Disorders Society's 13th International Congress of Parkinson's Disease and Movement Disorders, 7 – 11 June 2009
   Google Scholar
• Muhlack S, Woitalla D, Welnic J, Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. Neurosci Lett 2004;363(3):284-7
   PubMed Web of Science ®Google Scholar
• Murata M, Mizusawa H, Yamanouchi H, Kanazawa I. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off. J Neural Transm 1996;103(10):1177-85
   PubMed Web of Science ®Google Scholar
• Woitalla D, Goetze O, Kim JI, Levodopa availability improves with progression of Parkinson's disease. J Neurol 2006;253(9):1221-6
   PubMed Web of Science ®Google Scholar
• Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41(4):261-309
   PubMed Web of Science ®Google Scholar
• Muller T, Erdmann C, Bremen D, Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 2006;29(2):61-7
   PubMed Web of Science ®Google Scholar
• Contin M, Riva R, Martinelli P, Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease. Neurology 1996;46(4):1055-8
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Juncos J, Mouradian MM, Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21(4):370-6
   PubMed Web of Science ®Google Scholar
• Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology 1987;37(6):940-4
   PubMed Web of Science ®Google Scholar
• Muller T, Woitalla D, Saft C, Kuhn W. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord 2000;6(3):171-3
   PubMed Web of Science ®Google Scholar
• Crevoisier C, Zerr P, Calvi-Gries F, Nilsen T. Effects of food on the pharmacokinetics of levodopa in a dual-release formulation. Eur J Pharm Biopharm 2003;55(1):71-6
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Ziv I, Melamed E. Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease. Isr J Med Sci 1996;32(12):1224-7
   PubMedGoogle Scholar
• Goetze O, Wieczorek J, Mueller T, Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci Lett 2005;375(3):170-3
   PubMed Web of Science ®Google Scholar
• Goetze O, Nikodem AB, Wiezcorek J, Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil 2006;18(5):369-75
   PubMed Web of Science ®Google Scholar
• Minea D, Varga I, Falup-Pecurariu C, Influence of the dopamine agonist alpha-dihydroergocryptine on the pharmacokinetics of levodopa in patients with Parkinson's disease. Clin Neuropharmacol 2001;24(4):235-8
   PubMed Web of Science ®Google Scholar
• Fuente-Fernandez R, Ruth TJ, Sossi V, Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001;293(5532):1164-6
   PubMed Web of Science ®Google Scholar
• Fuente-Fernandez R, Phillips AG, Zamburlini M, Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 2002;136(2):359-63
   PubMed Web of Science ®Google Scholar
• Goetz CG, Laska E, Hicking C, Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 2008;23(5):700-7
   PubMed Web of Science ®Google Scholar
• Kurlan R, Rothfield KP, Woodward WR, Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility. Neurology 1988;38(3):419-21
   PubMed Web of Science ®Google Scholar
• Muller T, Woitalla D, Goetze O, Erdmann C. Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease. Mov Disord 2008;23(10):1458-61
   PubMed Web of Science ®Google Scholar
• Muller T, Kolf K, Ander L, Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. Clin Neuropharmacol 2008;31(3):134-40
   PubMed Web of Science ®Google Scholar
• Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59(6):1233-50
   PubMed Web of Science ®Google Scholar
• Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51(5):1309-14
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42(5):747-55
   PubMed Web of Science ®Google Scholar
• Brooks DJ, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003;74(8):1071-9
   PubMed Web of Science ®Google Scholar
• Hauser RA, Panisset M, Abbruzzese G, Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2009;24(4):541-50
   PubMed Web of Science ®Google Scholar